Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
Provided By GlobeNewswire
Last update: Sep 19, 2025
– Approval triggers $10 million cash milestone payment to Verrica –
– YCANTH® approval in Japan addresses significant unmet need of patients with molluscum –
Read more at globenewswire.comNASDAQ:VRCA (10/17/2025, 8:00:02 PM)
4.15
-0.08 (-1.89%)
Find more stocks in the Stock Screener
